Target Ambulatory Care NovaSight’s CureSight and EyeSwiftPRO address pediatric vision impairments, including amblyopia, with home-based, AI-driven screening and therapy. Sales opportunities exist with pediatric clinics, ophthalmology practices, and school-based vision programs seeking engaging, compliant, at-home treatment and remote monitoring capabilities.

FDA Clearance Advantage CureSight gained FDA 510(K) clearance and has a track record of regulatory progress, enabling easier entry into U.S. markets and reassuring potential buyers about safety and efficacy. Leverage this in conversations with hospital procurement and regional health authorities seeking validated digital therapeutics.

Telemedicine Enablement The platform’s real-time monitoring, caregiver feedback, and telemedicine features support remote follow-ups and data sharing. This aligns with value propositions for multisite clinics, bundled care models, and patient-centered programs needing scalable, remote patient management.

Growth through Partnerships Funding history and leadership hires in sales and marketing indicate a focus on scaling commercialization, including North America. Opportunities exist to partner with distributors, payer programs, and medical device networks to broaden reach and drive adoption of CureSight in new regions.

Global Market Need Amblyopia affects a sizable pediatric population, with traditional methods suffering from compliance and accuracy issues. NovaSight’s automated eye-tracking solutions offer a compelling replacement or augmentation, presenting upsell potential to clinics upgrading to digital, objective screening tools and to insurers seeking preventive care efficiencies.